Full Text
EE513 Assessing the Economic Impact of Biosimilars in the U.S.: A cost analysis of Infliximab, Trastuzumab, and Rituximab

Abstract

Authors

Seungjae Yi Minyoung Jang Taek Kwon

Back to Volume 28, Supplemental Issue 6S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×